Apexigen, Inc. (Nasdaq: APGN), relating to its proposed sale to Pyxis Oncology, Inc. Under the terms of the agreement, APGN shareholders are expected to receive 0.1725 shares of Pyxis per share they own.
Apexigen, Inc. (Nasdaq: APGN), relating to its proposed sale to Pyxis Oncology, Inc. Under the terms of the agreement, APGN shareholders are expected to receive 0.1725 shares of Pyxis per share they own.